ATE404217T1 - Therapie mit lipoproteinlipase (lpl) variant - Google Patents

Therapie mit lipoproteinlipase (lpl) variant

Info

Publication number
ATE404217T1
ATE404217T1 AT00943499T AT00943499T ATE404217T1 AT E404217 T1 ATE404217 T1 AT E404217T1 AT 00943499 T AT00943499 T AT 00943499T AT 00943499 T AT00943499 T AT 00943499T AT E404217 T1 ATE404217 T1 AT E404217T1
Authority
AT
Austria
Prior art keywords
lpl
lipoprotein lipase
therapy
variant
conditions
Prior art date
Application number
AT00943499T
Other languages
German (de)
English (en)
Inventor
Michael Hayden
John Kastelein
Katherine Julia Diane Excoffon
Original Assignee
Univ British Columbia
Amsterdam Molecular Therapeutics Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia, Amsterdam Molecular Therapeutics Bv filed Critical Univ British Columbia
Application granted granted Critical
Publication of ATE404217T1 publication Critical patent/ATE404217T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01034—Lipoprotein lipase (3.1.1.34)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
AT00943499T 1999-06-24 2000-06-23 Therapie mit lipoproteinlipase (lpl) variant ATE404217T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99202048 1999-06-24

Publications (1)

Publication Number Publication Date
ATE404217T1 true ATE404217T1 (de) 2008-08-15

Family

ID=8240356

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00943499T ATE404217T1 (de) 1999-06-24 2000-06-23 Therapie mit lipoproteinlipase (lpl) variant

Country Status (12)

Country Link
US (1) US20110201673A1 (enExample)
EP (1) EP1200117B1 (enExample)
JP (1) JP5095894B2 (enExample)
AT (1) ATE404217T1 (enExample)
AU (1) AU5799200A (enExample)
CA (1) CA2370081C (enExample)
CY (1) CY1108511T1 (enExample)
DE (1) DE60039880D1 (enExample)
DK (1) DK1200117T3 (enExample)
ES (1) ES2311464T3 (enExample)
PT (1) PT1200117E (enExample)
WO (1) WO2001000220A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005015687D1 (de) * 2004-03-02 2009-09-10 Cellectar Inc Phospholipid-analoga für die behandlung von krebs
ES2306163T3 (es) * 2004-06-21 2008-11-01 Amsterdam Molecular Therapeutics B.V. Tratamiento de esteatohepatitis no alcoholica (nash).
PT3272872T (pt) 2005-10-20 2020-06-26 Uniqure Ip Bv Vetores aav melhorados produzidos em células de insetos
WO2007148971A2 (en) 2006-06-21 2007-12-27 Amsterdam Molecular Therapeutics B.V. Vectors with modified initiation codon for the translation of aav-rep78 useful for production of aav in insect cells
HUE029744T2 (en) 2007-07-26 2017-04-28 Uniqure Ip Bv Baculoviral vectors comprising repeated coding sequences with differential codon biases
WO2009030254A1 (en) * 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
EP2432497A1 (en) * 2009-05-18 2012-03-28 Amsterdam Molecular Therapeutics (AMT) IP B.V. Use of lipoprotein lipase (lpl) in therapy
DK3708192T3 (da) 2009-06-12 2023-11-06 Cellectar Inc Etherphospholipidforbindelser til behandling af cancer og billeddannelse og detektering af cancerstamceller
EP2545165B1 (en) 2010-03-11 2020-07-29 uniQure IP B.V. Mutated rep encoding sequences for use in aav production
WO2011122950A1 (en) 2010-04-01 2011-10-06 Amsterdam Molecular Therapeutics (Amt) Ip B.V. Monomeric duplex aav vectors
SG10201604810UA (en) 2012-02-07 2016-08-30 Global Bio Therapeutics Inc Compartmentalized method of nucleic acid delivery and compositions and uses thereof
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
WO2015137802A1 (en) 2014-03-10 2015-09-17 Uniqure Ip B.V. Further improved aav vectors produced in insect cells
MA41035A (fr) * 2014-08-19 2017-08-15 Shire Human Genetic Therapies Lipoprotéine lipase pour le traitement d'affections liées à une hypertriglycéridémie, y compris la pancréatite aiguë
EP3458106A4 (en) * 2016-05-18 2020-03-18 Modernatx, Inc. POLYNUCLEOTIDS FOR CODING LIPOPROTEIN LIPASE FOR TREATING HYPERLIPIDEMIA
CA3045551A1 (en) 2016-12-16 2018-06-21 Uniqure Ip B.V. Immunoadsorption
US11452749B2 (en) 2017-07-10 2022-09-27 Uniqure Ip B.V. Means and methods for AAV gene therapy in humans
WO2019016349A1 (en) 2017-07-20 2019-01-24 Uniqure Ip B.V. PRODUCTION OF ENHANCED VAA CAPSIDS IN INSECT CELLS
CN111527201A (zh) 2017-12-29 2020-08-11 优尼科Ip有限公司 修饰的病毒载体及其制备和使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU695618B2 (en) * 1994-04-11 1998-08-20 Baylor College Of Medicine Compositions and methods for gene therapy to treat disease
US5658729A (en) * 1994-10-11 1997-08-19 The University Of British Columbia Method, reagent and kit for evaluating susceptibility to premature atherosclerosis

Also Published As

Publication number Publication date
CY1108511T1 (el) 2014-04-09
AU5799200A (en) 2001-01-31
DE60039880D1 (en) 2008-09-25
JP2003503355A (ja) 2003-01-28
DK1200117T3 (da) 2008-11-17
JP5095894B2 (ja) 2012-12-12
WO2001000220A2 (en) 2001-01-04
EP1200117A2 (en) 2002-05-02
WO2001000220A3 (en) 2001-07-12
CA2370081A1 (en) 2001-01-04
CA2370081C (en) 2014-06-03
US20110201673A1 (en) 2011-08-18
PT1200117E (pt) 2008-11-26
EP1200117B1 (en) 2008-08-13
ES2311464T3 (es) 2009-02-16

Similar Documents

Publication Publication Date Title
DE60039880D1 (en) Therapie mit lipoproteinlipase (lpl) variant
EP1918300A3 (en) Peptide-based immunization therapy for treatment of atherosclerosis
DE69834267D1 (de) Gentherapeutische verfahren zur bereitstellung von apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dyslipidämischer erkrankungen
ATE462006T1 (de) Isoform des vegfs
BR9707819A (pt) Imunogenos peptidicos
DE60032367D1 (de) Aktivierbare rekombinante neurotoxine
DE69636453D1 (de) Modulation der aktivität des cholesteryl-ester-transfer-proteins (cetp)
DE60039050D1 (de) Antigene meningokokken peptide
DE69905476D1 (en) Phosphonsaürederivate als ptp-1b-inhibitoren
FI970579A0 (fi) Andenovirus, joka käsittää glutationiperoksidaasia koodittavan geenin
ATE304052T1 (de) Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
BR9710975A (pt) Genes de proteìna de adesão de superfìcie exposta de 120 kda imunodominante de ehrlichia chaffeensis
DE59906362D1 (de) Verwendung von lipopeptiden oder lipoproteinen zur wundbehandlung
KR20040078639A (ko) 카세인 유도 펩타이드 및 이들의 치료 용도
ATE374246T1 (de) Polypeptidfragmente mit einem c-terminalen teil von katalase aus helicobacter
ATE214708T1 (de) Kationische mittel zur transfektion von nukleinsäuren
DE69712907D1 (de) Immunogene tlp-zusammensetzung
PT1294874E (pt) Variantes de cd154 e as suas utilizacoes
ATE278014T1 (de) Target zur behandlung von atherosklerose, fettleibigkeit und diabetis typ ii
DE60124380D1 (de) Angiogenese-assoziierte proteine und dafür kodierende nukleinsäure
ATE375390T1 (de) G-protein-gekoppelter rezeptor-ähnliche proteine
NO964894L (no) Rekombinante viruser, deres fremstilling samt anvendelse av genterapi
ATE427961T1 (de) Mit fettzellendifferenzierung assoziiertes gen und protein
SE9604439D0 (sv) New receptor

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1200117

Country of ref document: EP